Evaluation of the DPP II Assay in Laos

Acute Febrile Illness Clinical Trial

Official title:

Performance Assessment of the DPP Fever Panel II Assay for Detection of Infectious Causes of Acute Febrile Illness in Laos

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04299607
• Other study ID #: FE004
• Status: Completed
• Start date: November 12, 2019
• Est. completion date: November 30, 2020

Study information

• Verified date: March 2021
• Source: Foundation for Innovative New Diagnostics, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fever is the most frequent symptom in patients seeking care globally. Several causative agents of febrile illness have been described with a high prevalence in South East Asia. They include malaria, dengue, Rickettsia, Leptospira and Burkholderia species. Since their introduction in the market, rapid diagnostic tests for malaria have driven patient management and care. Malaria negative cases are commonly treated with antibiotics without confirmation of bacteraemia. This can be explained by conventional laboratory diagnostic tests such as blood culture that usually require a skilled staff and appropriate facilities. Several Rapid Diagnostic tests (RDTs) are currently in the market but only limited data on their performance are available, rendering them unsuitable to replace laboratory conventional tests. In addition, RDTs have been developed for single disease diagnosis and remain costly for Low and Middle Income Countries (LMIC). Chembio, in collaboration with FIND (Foundation for Innovative New Diagnostics) and MORU (Mahidol Oxford Tropical Medicine Research Unit), has developed a multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect serum immunoglobulin M (IgM) and specific microbial antigen of the most common agents of Acute Febrile Illness (AFI) in Asia. The assay comes with a reader that provides results interpretation to the operator. So far, DPP II assay performance has been estimated using a limited number of retrospective serum samples. More data are required to assess the performance of the assay using prospective serum samples. In addition, only limited data are available regarding the performance of the assay using blood samples. FIND will conduct a clinical trial to estimate the clinical performance of the assay in comparison to reference tests, using blood and serum samples and in intended settings of use.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: November 30, 2020
• Est. primary completion date: November 30, 2020
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Participants > 12 years old enrolled in the "Prospective study of the causes of fever amongst patients admitted to Mahosot Hospital, Vientiane, Lao PDR" (UI-2 study).
• Fever (= 37.5 °C)
• Illness duration < 14 days
• Willingness to provide blood samples by venepuncture

Exclusion Criteria:

• Absence of consent (and assent for children) to participate to the "Prospective study of the causes of fever amongst patients admitted to Mahosot Hospital, Vientiane, Lao PDR" (UI-2 study).
• Non-infectious known or suspected cause of fever
• No left over blood sample or insufficient volume of left over sample

Related Conditions & MeSH terms

• Acute Febrile Illness
• Fever

Intervention

Diagnostic Test:
• DPP Fever Panel II assay and DPP Micro Readers
Detection of common causes of acute febrile illnesses in Asia

Locations

Country	Name	City	State
Lao People's Democratic Republic	LOMWRU, Mahosot Hospital	Vientiane

Sponsors (1)

Lead Sponsor	Collaborator
Foundation for Innovative New Diagnostics, Switzerland

Country where clinical trial is conducted

Lao People's Democratic Republic, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of samples with concordant results for marker detection in paired whole blood and serum samples for each reader	The percentage of samples with concordant results using two types of assay readers will be calculated for each marker and each specimen type (blood and serum)	5 months
Primary	Optimal reader cut-offs for serum samples and for blood samples to obtain the overall highest diagnostic accuracy per sample type	The reader cut-offs (numerical values) that give the highest specificity and specificity will calculated for each marker and reader	5 months
Primary	Percentage of more targeted treatments that would have been prescribed if the DPP II assay test was used in routine in comparison to actual prescribed treatments and to treatment that would have been prescribed based on comparator tests	In comparison to reference tests and routine tests, the impact of the DPP Fever Panel II assay on antibiotic prescriptions will be modeled	5 months
Primary	Cost impact of more targeted treatments that would have been prescribed if the DPP II assay test was used in routine in comparison to actual prescribed treatments and to treatment that would have been prescribed based on comparator tests	In comparison to reference tests and routine tests, the impact of the DPP Fever Panel II assay on health costs will be modeled.	5 months
Secondary	Estimates of sensitivity and specificity of the DPP assay for detection of fever causative agents using venous blood samples, in comparison to reference tests		5 months
Secondary	Estimates of sensitivity and specificity of the DPP assay for detection of fever causative agents using serum samples, in comparison to reference tests.		5 months
Secondary	Estimates of operational characteristics, including invalid and indeterminate rates	The % of invalid results and indeterminate rates will be calculated.	5 months
Secondary	Estimates of ease-of-use will be captured through user-appraisal questionnaire.	Answers to each question will be graded either positive, neutral or negative. The % and absolute numbers of positive, neutral and negative answers will be reported in tables and charts.	5 months